Dexcom (DXCM) View Exceeds Estimates; Shareholder Keeps Betting on Affimed (AFMD)
DexCom, Inc. (Nasdaq:DXCM) closed at $70.65, down $4.79 (or -6.35%), with a total volume of 2,264,210 shares traded on Wednesday.
DXCM shares soared more than 13% in the extended session as the company reported third quarter 2015 preliminary revenues of about $105 million, representing a 52% increase year-over-year and easily surpassing the Capital IQ Consensus Estimate of $97.67 million in revenues for the period
Dexcom, a medical device company, has 80.08M Shares Outstanding, Market Capitalization (intraday) of $5.66B and DXCM stock 52-week range is between $40.39 and $103.29 per share.
Affimed N.V. (Nasdaq:AFMD) finished Wednesday’s trading session at $6.14, up $0.05 (or +0.82%), and 128,942 of its shares exchanged hands during the day
Affimed said after the closing bell that an existing shareholder purshased 3.3 million shares of the company for $21.8 million
AFMD shares climbed over 5% following the company’s announcement
Affimed, a clinical-stage biopharmaceutical company, has 29.73M Shares Outstanding, Market Capitalization (intraday) of $182.57M and AFMD stock one-year range is $3.55 – $24.20 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/